BDX.SW Becton, Dickinson Earnings Preview May 7

Becton, Dickinson and Company (BDX.SW) reports earnings on May 7, 2026. Analysts expect the medical device giant to deliver $2.22 earnings per share and $3.73 billion in revenue. The healthcare company operates three core segments: BD Medical, BD Life Sciences, and BD Interventional. With a $72.55 billion market cap, BDX.SW is a major player in medical supplies, diagnostic products, and laboratory equipment. Investors will focus on segment performance, margin trends, and guidance. The company’s recent financial growth shows mixed signals, with strong earnings momentum offset by modest revenue expansion. Understanding what analysts expect helps investors prepare for potential market moves.

Earnings Estimates and What They Mean

Analysts project Becton, Dickinson will report $2.22 earnings per share and $3.73 billion in quarterly revenue. These estimates reflect expectations for steady performance across the company’s three business segments.

EPS Expectations

The $2.22 EPS estimate represents analyst consensus for profitability. This figure matters because it shows whether the company can convert revenue into actual earnings. Becton, Dickinson’s trailing twelve-month EPS stands at $5.371, suggesting quarterly earnings typically run lower than annual averages. The estimate implies continued operational efficiency and cost management.

Revenue Forecast

The $3.73 billion revenue estimate indicates expected sales across all segments. This translates to roughly $12.6 billion annualized, consistent with the company’s recent trajectory. Revenue growth has been modest at 4.16% year-over-year, reflecting mature market conditions in medical devices. Analysts expect this trend to continue without major acceleration or decline.

Historical Performance and Beat/Miss Patterns

Becton, Dickinson’s recent financial growth reveals important trends for predicting earnings outcomes. The company shows strong earnings growth but slower revenue expansion, creating a mixed picture.

Earnings Momentum

Net income grew 14.89% year-over-year, while EPS expanded 18.31%. This outpaced revenue growth of just 4.16%, indicating margin expansion and share buybacks. Operating income jumped 13.55%, showing improved operational leverage. This pattern suggests management is executing well on profitability despite revenue headwinds.

Revenue Trends

Revenue growth of 4.16% is modest but stable. Three-year revenue growth turned slightly negative at -0.51%, but five-year growth reached 8.72%. This suggests the company faced recent headwinds but maintains long-term growth capability. Gross profit grew 11.69%, outpacing revenue, which confirms margin improvement is real.

Prediction: Likely Beat

Given strong earnings growth and margin expansion, Becton, Dickinson appears positioned to meet or slightly beat EPS estimates. Revenue could meet expectations, though upside surprises seem limited given modest growth trends.

Key Metrics and Financial Health

Becton, Dickinson’s balance sheet and operational metrics reveal a financially stable company managing debt effectively while generating solid cash flow.

Profitability Ratios

Net profit margin stands at 7.31%, while operating margin reached 13.62%. Return on equity is 4.60%, which is modest but acceptable for a mature healthcare company. The company maintains a 70.27 P/E ratio, indicating investors price in steady but not explosive growth. Gross margin of 44.55% provides cushion for operational expenses.

Cash Flow Strength

Operating cash flow per share totals $6.07, while free cash flow reaches $4.85 per share. The company generates strong cash despite capital intensity. Free cash flow yield of 1.92% shows cash generation relative to market value. Dividend per share of $1.67 is well-covered by cash flow, indicating sustainable shareholder returns.

Debt Management

Debt-to-equity ratio of 0.76 is moderate for healthcare. Interest coverage of 4.73x shows the company comfortably services debt. Net debt to EBITDA of 4.70x is reasonable. The company carries $54.81 in debt per share against $2.26 in cash per share, reflecting strategic leverage rather than distress.

What Investors Should Watch

The May 7 earnings call will reveal critical information about Becton, Dickinson’s strategic direction and market conditions.

Segment Performance

Investors should monitor BD Medical, BD Life Sciences, and BD Interventional separately. Medical segment strength indicates demand for syringes, catheters, and infusion systems. Life Sciences performance reflects diagnostic and research demand. Interventional results show surgical and intervention product traction. Segment margins matter more than total revenue.

Guidance and Outlook

Management guidance for the next quarter and full year will signal confidence. Any changes to annual EPS or revenue targets could drive stock movement. Commentary on pricing power, volume trends, and competitive pressures matters. Guidance beats or misses often trigger larger moves than actual earnings.

Margin Trends

Watch for gross margin stability or expansion. Operating margin trends indicate cost control. Management commentary on supply chain, labor costs, and manufacturing efficiency will guide future profitability. Margin compression would concern investors despite revenue growth.

Final Thoughts

Becton, Dickinson and Company enters its May 7 earnings report with strong momentum in profitability and margins, though revenue growth remains modest. Analysts expect $2.22 EPS and $3.73 billion in revenue, reflecting steady operational performance. The company’s 14.89% net income growth and 18.31% EPS expansion suggest management is executing well on cost control and efficiency. Meyka AI rates BDX.SW with a grade of B, reflecting solid fundamentals balanced against moderate growth prospects. This grade factors in S&P 500 benchmark comparison, sector performance, financial growth, key metrics, and analyst consensus. Invest…

FAQs

Disclaimer:

Stock markets involve risks. This content is for informational purposes only. Earnings estimates are analyst projections and not guarantees of actual results. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.